Chronic DLL4 blockade induces vascular neoplasms
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Delta-like 4 (DLL4)-mediated Notch signalling has emerged as an attractive target for cancer therapy. However, the potential side effects of blocking this pathway remain uncertain. Here we show that chronic DLL4 blockade causes pathological activation of endothelial cells, disrupts normal organ homeostasis and induces vascular tumours, raising important safety concerns.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [141]
Citations
Cites
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Self-citationHsieh, S. H., Ying, N. W., Wu, M. H., Chiang, W. F., Hsu, C. L., Wong, T. Y., Jin, Y. T., Hong, T. M., & Chen, Y. L. (2008) · Oncogene · doi:10.1038/sj.onc.1211029 · Cited by 229
Schmidt, M., Paes, K., De Mazière, A., Smyczek, T., Yang, S., Gray, A., French, D., Kasman, I., Klumperman, J., Rice, D. S., et al. (2007) · Development · doi:10.1242/dev.002576 · Cited by 183
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications
Li, J., & Harris, A. L. (2009) · Frontiers in bioscience · doi:10.2741/3438 · Cited by 141
Promoting angiogenesis to a fault
Hicklin, D. J. (2007) · Nature Biotechnology · doi:10.1038/nbt0307-300 · Cited by 13
Different roads to inactivation
Seton-Rogers, S. E. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2719 · Cited by 8
Flintoft, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2081 · Cited by 1
Cited by
Items 201–280 of 280
García-Pascual, C. M., Ferrero, H., Zimmermann, R. C., Simón, C., Pellicer, A., & Gómez, R. (2014) · Placenta · doi:10.1016/j.placenta.2014.03.019 · Cited by 13
Principal signalling complexes in haematopoiesis: Structural aspects and mimetic discovery
Tarasova, A., Haylock, D. N., & Winkler, D. A. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.09.001 · Cited by 12
Investigational Notch and Hedgehog inhibitors – therapies for cardiovascular disease
Redmond, E. M., Guha, S., Walls, D., & Cahill, P. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.628658 · Cited by 16
The Hajdu Cheney Mutation Is a Determinant of B-Cell Allocation of the Splenic Marginal Zone
Yu, J., Zanotti, S., Walia, B., Jellison, E. R., Sanjay, A., & CANALIS, E. M. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.09.010 · Cited by 13
“AlthoughNotch2 neutralizationwas achieved by the use of anti-Notch2 NRR antibodies without negative consequences, Notch neutralization has been reported to cause vascular tumors and gastrointestinal toxicity.(63,64) The reasonwe did not encounter these complications probably was related to the low dose and limited dur…”
BackgroundNotch signaling in hematopoietic cell transplantation and T cell alloimmunity
Ebens, C. L., & Maillard, I. P. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.08.001 · Cited by 14
“In addition, it has translational importance, as the use of short-term Notch blockade would mitigate safety concerns related to prolonged Notch inhibition in patients [43,75,93].”
BackgroundYao, Z., & Sherif, Z. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11316 · Cited by 11
“Furthermore, Notch-1 has been identified as a tumor suppressor in mouse prostate and skin [12, 28, 36].”
BackgroundJarzabek, M. A., Proctor, W. R., Vogt, J., Desai, R. M., Dicker, P., Cain, G. R., Raja, R. G., Brodbeck, J., Stevens, D., van der Stok, E. P., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198099 · Cited by 11
Thirant, C., Gavard, J., Junier, M., & Chneiweiss, H. (2013) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201200102 · Cited by 11
“However, DLL-4-blocking antibodies need to be tightly dosed as a chronic blockade can induce vascular neoplasms [84].”
BackgroundXuan, S., Shin, D. H., & Kim, J. (2014) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-014-0151-2 · Cited by 10
“Despite the availability of efficient Notch inhibitors such as c-secretase inhibitors (GSI), peptides (Moellering et al. 2009) or antibodies (Wu et al. 2010; Yan et al. 2010), the GSIs are the only form of Notch inhibitors in clinical trials (Purow 2012).”
BackgroundHu, Y. F., & Li, H. (2023) · Journal of Oral Rehabilitation · doi:10.1111/joor.13642 · Cited by 10
Perspectives on the discovery of NOTCH2‐specific inhibitors
Dobranowski, P., Ban, F., Contreras‐Sanz, A., Cherkasov, A. R., & Black, P. C. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13132 · Cited by 10
Arteriogenesis versus angiogenesis
Carmeliet, P., Eelen, G., & Kalucka, J. M. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0008 · Cited by 8
Influence of the Notch system in the therapeutic response of American tegumentary leishmaniasis
Rodrigues, K. M. P., de Oliveira, M. P., Maretti-Mira, A. C., Oliveira-Neto, M. P., Mattos, M. S., Silva, L., Soares, D. A., Dolci, E. L. L., Perico, R. A. P. N., & Pirmez, C. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10240.x · Cited by 8
Proia, T. A., Jiang, F., Bell, A., Nicoletti, R., Kong, L., Kreuter, K. A., Poling, L. L., Winston, W. M., Flaherty, M. M., Weiler, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1104 · Cited by 8
“Moreover, no signs of vascular neoplasm were observed, as has been reported for some DLL4 and Notch1 inhibitors (34).”
BackgroundNasrin, A., Hassan, M., & Ye, P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.082 · Cited by 8
Context- and Cell-Dependent Effects of Delta-Like 4 Targeting in the Bone Marrow Microenvironment
Remédio, L., Carvalho, T., Caiado, F., Bastos-Carvalho, A., Martins, D. F., Duarte, A., Yagita∥, H., & Dias, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052450 · Cited by 8
“The BM vascular modifications herein described were accompanied by systemic defects in the vascular compartment of the liver (Figure S4), as previously reported by others [56].”
The role of the Notch signaling pathway in liver injury and repair
Yue, Z., Ruan, B., Duan, J., Han, H., & Wang, L. (2018) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000014 · Cited by 7
The Missed Notch to Bring Down Diabetes
Mirtschink, P., & Chavakis, T. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.03.011 · Cited by 7
Ahmed, S., Arif, A., Abbas, S., Khan, M. O., Kirmani, S., & Khan, A. H. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.01.041 · Cited by 7
Sargis, T., Youn, S., Thakkar, K., Naiche, L. A., Paik, N. Y., Pajcini, K. V., & Kitajewski, J. (2022) · Angiogenesis · doi:10.1007/s10456-022-09861-6 · Cited by 7
“Despite its promise, anti-DLL4 therapy evaluated in preclinical animal models resulted in pathological changes in the liver as well as severe vascular neoplasms [16].”
BackgroundShafiee, S., Jagtap, J. M. M., Zayats, M., Epperlein, J. P., Banerjee, A., Geurts, A. M., Flister, M. J., Zhuk, S. M., & Joshi, A. (2023) · Cancers · doi:10.3390/cancers15051460 · Cited by 6
“While DLL4 blockade is an attractive therapy, long-term extended use of DLL4 mAbs has demonstrated concerning off-target effects [77,78].”
BackgroundRuppel, J., Brady, A., Elliott, R., Leddy, C., Marco, P., Coleman, D. R., Couch, J. A., & Wakshull, E. (2016) · Journal of Immunology Research · doi:10.1155/2016/2921758 · Cited by 6
“Although anti-DLL4 full length antibody showed potent antitumor activity, nonclinical in vivo testing resulted in unmanageable toxicity, with vascular and liver toxicities [13].”
The role of DLL1 in long-term vascular normalization and cancer immunotherapy
Wu, Q., & Huang, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0507 · Cited by 6
Heinzelmann, K., Fysikopoulos, A., Jaquin, T. J., Peper-Gabriel, J. K., Hansbauer, E.-M., Grüner, S., Prassler, J., Wurzenberger, C., Kennedy, J. G. C., Snead, J. Y., et al. (2024) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00059.2024 · Cited by 6
Mechanisms of Tumor Angiogenesis
Zuazo-Gaztelu, I., & Casanovas, O. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_1 · Cited by 7
Osherovich, L. Z. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.151 · Cited by 4
FHL1C induces apoptosis in notch1-dependent T-ALL cells through an interaction with RBP-J
Fu, W., Wang, K., Zhao, J., Yu, H., Li, S., Yan, L., Liang, L., Huang, S., Liang, Y., Han, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-463 · Cited by 4
“Although anti-NRR antibodies have been developed, sustained treatment with these antibodies will likely cause vascular neoplasms [36].”
BackgroundHalpern, W., & Hutto, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415759-0.00025-x · Cited by 5
Yuwen, Y., Wang, X., Liu, J., Liu, Z., & Zhu, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20777 · Cited by 5
Role of Cytokines in Angiogenesis: Turning It On and Off
Thal, M. A., & Kishore, R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5857-9_3 · Cited by 4
Tarrant, J. M., Lewin-Koh, S.-C., & Lewin‐Koh, N. (2014) · Biomarkers · doi:10.3109/1354750x.2014.919026 · Cited by 3
“Liver toxicity was dose-related and characterized primarily by centrilobular hepatic sinusoidal dilation with adjacent hepatocellular atrophy (the DLL4 F(ab)2 is shown in Figure 1 and DLL4 mAb liver pathology in (Yan et al., 2010).”
BackgroundInfluentialMaintaining the Plexus: SYNJ2BP as a Novel Regulator of Angiogenesis
Mleynek, T., & Li, D. (2013) · Circulation Research · doi:10.1161/circresaha.113.302600 · Cited by 3
Inhibition of notch promotes liver metastasis
Banerjee, D., Kadenhe‐Chiweshe, A. V., & Yamashiro, D. J. (2015) · Aging · doi:10.18632/aging.100811 · Cited by 3
Endothelial-to-hematopoietic transition is induced by Notch glycosylation and upregulation of MycnPreprint
Laruy, B. L., García-Gónzalez, I., Casquero-García, V., & Benedito, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.13.295238 · Cited by 2
Tumorangiogenese und aktuelle therapeutische Möglichkeiten der Inhibition
Mogler, C., & Augustin, H. G. (2011) · Der Onkologe · doi:10.1007/s00761-011-2029-5 · Cited by 2
Brizzi, M. F., & Defilippi, P. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.18 · Cited by 2
“However, continuous dosing with anti-Dll4 mAb has resulted in new vessel formation and angiomas in different experimental models (19).”
BackgroundKumar, A., Desai, S., & Pandey, B. N. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.09.01 · Cited by 2
“Inhibition of Dll4 signaling has been found to promote tumor angiogenesis and vascular neoplasm in various tissue types suggesting an anti-angiogenic effect of Dll4 (8,9).”
BackgroundNotch Signaling in Skeletal Diseases
CANALIS, E. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11234-6 · Cited by 2
Shi, L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc271 · Cited by 2
Notch Signaling in the Normal Intestine and Intestinal Cancer
Espinosa, L., López‐Arribillaga, E., Bachs, O., & Bigas, A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8859-4_13 · Cited by 1
What Is the Meaning of Notch Pathway and How Can We Selectively Do the Targeting?
Custódio, A. S. S., & Barriuso, J. (2014) · Springer eBooks · doi:10.1007/978-94-017-8754-3_2 · Cited by 1
Beyond VEGF: The NOTCH and ALK1 Signaling Pathways as Tumor Angiogenesis Targets
Nolan-Stevaux, O., & Toni, H. (2012) · InTech eBooks · doi:10.5772/26834 · Cited by 1
“In other preclinical studies, pharmacological agents causing long term blockade, such as an anti-DLL4 antibody, also caused unexpected proliferative effects in select tissues (Yan et al., 2010).”
Background内皮细胞靶向的可溶性人源Delta-like 4抑制生理性与病理性眼部血管新生
李, 娜., 冯, 蕾., 晏, 贤., 刘, 瑗., 杨, 子., 王, 莉., 张, 毓., 窦, 国., 陈, 衍., 段, 娟., et al. (2015) · Scientia Sinica Vitae · doi:10.1360/zc2015-45-3-271
Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer
Frame, F. M., & Maitland, N. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6498-3_4 · Cited by 1
Notch in Human Cancers—A Complex Tale
Guo, H., Xie, T., & Liu, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00096-7 · Cited by 2
Stapor, P. C., Bock, K. D., & Carmeliet, P. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_10 · Cited by 2
The Vascular Endothelium in Cancer
Mahmoud, A. M., & Burloiu, C. A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_375 · Cited by 1
Stapor, P. C., Bock, K. D., & Carmeliet, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_10-1 · Cited by 1
Out on the Fringe: Modulation of Notch Signaling by Glycosylation
Xu, K., & Egan, S. E. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8859-4_4 · Cited by 1
The Hallmarks of Prostate Cancer Stem Cells
Maitland, N. J., & Collins, A. T. (2014) · doi:10.1002/9781118356203.ch2 · Cited by 1
Carlier, A., Geris, L., Bentley, K., Carmeliet, G., Carmeliet, P., & Oosterwyck, H. V. (2013) · PLoS Computational Biology · doi:10.1371/annotation/38264a13-d4b5-49cd-b54e-47330bb19fe9 · Cited by 1
Engaging the Immune Response to Normalize the Tumor Microenvironment
Chi-Sabins, N., & Storkus, W. J. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
VEGF and NOTCH in blood vessels, an intricate and fascinating interplay
Caolo, V. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20110511vc
Monroe, M. M., Hessman, C. J., Clayburgh, D. R., Bubbers, E. J., & Wong, M. H. (2011) · BiblioBoard Library Catalog (Open Research Library) · doi:10.5772/21228
Stewart, K. L. (2010) · Digital Commons-TMC (Texas Medical Center)
Notch one for activating NOTCH
Martz, L. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.953
Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance
Mier, J. W., Bhatt, R. S., Panka, D. J., & Atkins, M. B. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1622-1_16
“Despite these encouraging results, however, protracted DLL4 blockade was associated with the involution of the thymus, abnormalities in the hepatic sinusoids, and the development of subcutaneous tumors of vascular origin [ 25 ].”
ResultTargeting Key Stemness-Related Pathways in Human Cancers
Coyle, K. M., Thomas, M. L., Sultan, M., & Marcato, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_15 · Cited by 1
Isoniemi, K. O. (2016) · Doria (University of Helsinki) · Cited by 1
Notch Regulation in Breast Cancer
Izrailit, J. (2015) · TSpace (University of Toronto)
Tumor Blood Vessel-Associated Antigens as Targets for Cancer Immunotherapy
Fabian, K. P. (2017) · D-Scholarship@Pitt (University of Pittsburgh)
Top-NOTCH Regulation of Cardiac Metabolism
Lim, R., & Potente, M. (2018) · Circulation · doi:10.1161/circulationaha.118.033669
Sinicropi-Yao, S. L., Koenig, M. J., & Carbone, D. P. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8859-4_10
Rothweiler, S., & Semela, D. (2015) · Wiley eBooks · doi:10.1002/9781118663387.ch20
Endothelial Dll4/Notch Signaling as a Target for Cancer and Wound Healing Therapy
Trindade, A., Djokovic, D., Mendonça, L., Badenes, M., Lopes-da-Costa, L., & Duarte, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-61981-7_22
Targeting Self-renewal Pathways in Cancer Stem Cells
Maugeri‐Saccà, M., & Zeuner, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-2900-1_3
Endothelial Actin Cytoskeletonand Angiogenesis
Ochoa, C. D., Balczon, R., & Stevens, T. (2013) · CRC Press eBooks · doi:10.1201/b15421-4
Mechanisms of Tumor Angiogenesis
Zuazo-Gaztelu, I., & Casanovas, O. (2016) · Springer eBooks · doi:10.1007/978-3-319-31215-6_1-1
“Nevertheless, chronic Dll4 blockade results in vascular neoplasms (Yan et al. 2010).”
Mechanisms involved in quiescent blood vessel homeostasis
Fernández-Chacón, M. (2021) · Hispana
Regulation of enfothelial cell cycle dynamics by Notch during angiogenesis
Pontes-Quero, S. (2018) · doi:10.4321/repisalud.7737
Transcriptional states do not always predict vascular function and pathology
(2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00279-x
A Notch between vascular morphogenesis and transcriptional identity
Gómez-Salinero, J. M., & Rafii, S. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00282-2
Disrupting Notch signalling by a small molecule inhibiting dihydroorotate dehydrogenase activity
Braune, E.-B., Wienke, D., Seshire, A., Heinrich, T., Haraldsson, M., Laín, S., & Lendahl, U. (2026) · Scientific Reports · doi:10.1038/s41598-026-55679-3
The Role of Notch Signaling in T Cell-mediated Immune Disorders.
Sandy, A. R. (2013) · Deep Blue (University of Michigan)
The Differential Expression of EGFL7 Transcripts during Angiogenesis in Human Fibrosarcoma
Baktash, N. (2012) · Scholarship@Western (Western University)
Guo, C., Wei, X., Li, W., Wang, G., Gao, B., Zhang, L., & Gao, B. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04610-z
“Gamma-secretase inhibitors (GSIs), as potent Notch pathway inhibitors, exhibit broad recognition of gamma-secretase substrates, making them prone to off-target effects and adverse reactions, thus limiting their clinical translation [176–178].”
Wang, X., Zhang, X., Fan, H., Li, M., Tang, Y.-L., & Sheng, S. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb01432a
Bridge, G. E. M. (2013) · UCL Discovery (University College London)
Vascular Targeting of Adipose Tissue
Salameh, A., & Kolonin, M. G. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6819-6_15
Metadata
- Authors
- Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D.
- Affiliations
- Genentech (US)
- Venue
- Nature
- Published
- 2010-02
- Volume
- 463
- Issue
- 7282
- Pages
- E6-E7
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030370645
- Cited by
- 280
- References
- 8
- Citations by year
- 2026: 3 · 2024: 3 · 2023: 12 · 2022: 5 · 2021: 17 · 2020: 9 · 2019: 10 · 2018: 17 · 2017: 17 · 2016: 11 · 2015: 27 · 2014: 26 · 2013: 36 · 2012: 30
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- DLL4, Notch signaling, vascular tumors, endothelial activation, drug safety, cancer treatment side effects, organ homeostasis, angiogenesis
- MeSH terms
- Animals, Antineoplastic Agents, Calcium-Binding Proteins, Humans, Macaca fascicularis, Membrane Proteins, Signal Transduction, Vascular Neoplasms, Endothelial Cells, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Mice, Rats, Receptors, Notch, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.